TEL AVIV, Israel--(BUSINESS WIRE)--July 22, 2004--Tissera, Inc. (OTCBB:TSSR - News), has recently become aware that a patent application has been filed by Dr. Marc Hammerman at the Washington University in St. Louis in connection with the development of diabetes mellitus therapy based on transplanted embryonic pancreatic-precursor cells. We have conducted an analysis of Dr. Hammerman's patent and we have determined that Dr. Hammerman's patent may restrict our freedom to implement our pancreatic application. We do not believe Dr. Hammerman's patent will impact our liver, spleen and other organ applications.

About Tissera

Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera obtained the license for the worldwide exclusive rights to the technology developed at the Weizmann Institute of Science in Israel led by Professor Yair Reisner. In this research, scientists successfully implanted embryonic human and porcine organ precursor tissues in mice, which grew into functional organs. This research was published in Nature Medicine and attracted worldwide scientific and media attention.

Safe Harbor Statement

"Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing technology into a useful product, our moving forward with our plans for trials, and our plans to expand the Company's infrastructure. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to further finance our plans and unforeseen technical difficulties in developing our technology, which could among other things, delay or prevent product development and our planned results. For further risk factors see the Company's 10-KSB filed with the SEC for our latest fiscal year."